Business Description
NeuroBo Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US36870A1088
Description
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 85.5 | |||||
Equity-to-Asset | 0.59 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 82.2 | |||||
3-Year EPS without NRI Growth Rate | 80.9 | |||||
3-Year FCF Growth Rate | 76.2 | |||||
3-Year Book Growth Rate | -66.2 | |||||
Future 3-5Y EPS without NRI Growth Rate | 21.81 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 33.78 | |||||
9-Day RSI | 45.54 | |||||
14-Day RSI | 50.48 | |||||
6-1 Month Momentum % | 11.95 | |||||
12-1 Month Momentum % | -5.75 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.46 | |||||
Quick Ratio | 2.46 | |||||
Cash Ratio | 2.34 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -291.2 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -88.18 | |||||
ROA % | -65.33 | |||||
ROIC % | -718.39 | |||||
ROC (Joel Greenblatt) % | -11220.67 | |||||
ROCE % | -89.13 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.2 | |||||
Price-to-Tangible-Book | 2.2 | |||||
EV-to-EBIT | -1.74 | |||||
EV-to-Forward-EBIT | -1.22 | |||||
EV-to-EBITDA | -1.74 | |||||
EV-to-FCF | -1.99 | |||||
Price-to-Net-Current-Asset-Value | 2.26 | |||||
Price-to-Net-Cash | 2.45 | |||||
Earnings Yield (Greenblatt) % | -57.47 | |||||
FCF Yield % | -32.71 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NRBO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
NeuroBo Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -3.22 | ||
Beta | 0.05 | ||
Volatility % | 96.92 | ||
14-Day RSI | 50.48 | ||
14-Day ATR ($) | 0.357781 | ||
20-Day SMA ($) | 4.5994 | ||
12-1 Month Momentum % | -5.75 | ||
52-Week Range ($) | 2.9 - 6.7499 | ||
Shares Outstanding (Mil) | 10 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
NeuroBo Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
NeuroBo Pharmaceuticals Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
NeuroBo Pharmaceuticals Inc Frequently Asked Questions
What is NeuroBo Pharmaceuticals Inc(NRBO)'s stock price today?
The current price of NRBO is $4.51. The 52 week high of NRBO is $6.75 and 52 week low is $2.90.
When is next earnings date of NeuroBo Pharmaceuticals Inc(NRBO)?
The next earnings date of NeuroBo Pharmaceuticals Inc(NRBO) is 2024-08-09 Est..
Does NeuroBo Pharmaceuticals Inc(NRBO) pay dividends? If so, how much?
NeuroBo Pharmaceuticals Inc(NRBO) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |